{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-060044","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2023-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.058874+00:00","generated_at":"2026-06-18T13:12:04.888850+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Quince Therapeutics appoints Brendan Hannah as principal financial officer after Ted Monohon resigns","bullets":["Ted Monohon resigns as Chief Accounting Officer and VP of Finance, effective March 16, 2023; no disagreement with company.","Brendan Hannah, current Chief Business Officer, appointed as principal financial officer and principal accounting officer effective March 16, 2023.","Hannah's compensation unchanged; no family relationships or reportable transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-060044","json":"https://secwatch.observer/filing/0001193125-23-060044.json","markdown":"https://secwatch.observer/filing/0001193125-23-060044.md","text":"https://secwatch.observer/filing/0001193125-23-060044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/0001193125-23-060044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/d146910d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T13:12:04.888850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"911dfde97a","claim":"Ted Monohon resigned as Chief Accounting Officer and Vice President of Finance at Quince Therapeutics, Inc..","evidence_excerpt":"On March 1, 2023, Ted Monohon informed Quince Therapeutics, Inc. (the “ Company ”) of his intention to resign from his position as the Chief Accounting Officer and Vice President of Finance, including as the principal financial officer and principal accounting officer, effective as of March 16, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/0001193125-23-060044-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Accounting Officer and Vice President of Finance"}],"fact_type":"executive_change"},{"claim_id":"c57681cbf5","claim":"Brendan Hannah was appointed as principal financial officer and principal accounting officer at Quince Therapeutics, Inc..","evidence_excerpt":"On March 3, 2023, the Board of Directors of the Company appointed Brendan Hannah, Chief Business Officer of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of March 16, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/0001193125-23-060044-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}